𝔖 Bobbio Scriptorium

✦ LIBER ✦

PP52. Determinants of treatment costs for stage III and IV colon cancer patients in Latvia. Evaluation of oral treatment with Ftorafur and Ftorafur/Leucovorin

✍ Scribed by S Plate; J Berzins

Book ID: 117665330
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 164 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)85965-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN59 REAL-WORLD COSTS OF ADJUVANT TREAT

PCN59 REAL-WORLD COSTS OF ADJUVANT TREATMENT FOR STAGE III COLON CANCER PATIENTS IN THE NETHERLANDS

✍ CWM van Gils; SS Tan; WK Redekop; CJA Punt 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN191 Economic Evaluation of XELOX vs F

PCN191 Economic Evaluation of XELOX vs FOLFOX4 as Adjuvant Treatment for Patients with Stage III Colon Cancer in south Korea

✍ Kim, C.M.; Ju, S.Y.; Kim, S.H.; Kang, M.; Park, J.; Choi, W.S. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

6075 POSTER Phase III Trial of Treatment

6075 POSTER Phase III Trial of Treatment Duration of Oral Uracil and Tegafur/Leucovorin Adjuvant Chemotherapy for Patients (pts) With Stage Mb/Ill Colon Cancer – an Interim Safety and Feasibility Report, JFMC33-0502

✍ Sasaki, K.; Sadahiro, S.; Tsuchiya, H.; Kondo, K.; Katsumata, K.; Nishimura, G.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Adjuvant chemotherapy with oxaliplatin,

Adjuvant chemotherapy with oxaliplatin, in combination with fluorouracil plus leucovorin prolongs disease-free survival, but causes more adverse events in people with stage II or III colon cancer: Abstracted from: André T, Boni C, Mounedji-Boudiaf L, et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–51

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 213 KB

Treatment Rationale and Study Design for

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

✍ Jyoti D. Patel; Philip Bonomi; Mark A. Socinski; Ramaswamy Govindan; Shengyan Ho 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 100 KB